CVS has been the topic of a number of other reports. Needham & Company LLC reiterated a hold rating on shares of CVS Health in a research report on Sunday, September 10th. Oppenheimer reiterated a buy rating and issued a $95.00 price target on shares of CVS Health in a research report on Monday, October 9th. Leerink Swann reiterated an outperform rating and issued a $85.00 price target (down from $90.00) on shares of CVS Health in a research report on Tuesday, November 7th. BidaskClub downgraded shares of CVS Health from a hold rating to a sell rating in a research report on Friday, August 25th. Finally, SunTrust Banks set a $85.00 price target on shares of CVS Health and gave the company a buy rating in a research report on Thursday, October 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $86.35.
CVS Health (NYSE:CVS) opened at $71.38 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 52-week low of $66.45 and a 52-week high of $84.72. The stock has a market cap of $72,621.40, a PE ratio of 12.56, a price-to-earnings-growth ratio of 1.23 and a beta of 0.89.
In related news, COO Jonathan C. Roberts sold 85,743 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the completion of the sale, the chief operating officer now directly owns 119,555 shares of the company’s stock, valued at approximately $9,939,802.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Thomas M. Moriarty sold 20,547 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the sale, the executive vice president now directly owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 714,125 shares of company stock valued at $58,119,381. 0.61% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of CVS. AXA grew its stake in shares of CVS Health by 14.8% during the 3rd quarter. AXA now owns 681,252 shares of the pharmacy operator’s stock worth $55,399,000 after acquiring an additional 87,634 shares in the last quarter. Shelton Capital Management grew its stake in shares of CVS Health by 19.4% during the 3rd quarter. Shelton Capital Management now owns 52,860 shares of the pharmacy operator’s stock worth $4,299,000 after acquiring an additional 8,574 shares in the last quarter. Chicago Partners Investment Group LLC grew its stake in shares of CVS Health by 204.9% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 10,667 shares of the pharmacy operator’s stock worth $867,000 after acquiring an additional 7,169 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of CVS Health during the 3rd quarter worth approximately $1,365,000. Finally, Public Employees Retirement System of Ohio grew its stake in shares of CVS Health by 0.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 728,256 shares of the pharmacy operator’s stock worth $59,222,000 after acquiring an additional 2,594 shares in the last quarter. 82.24% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Loop Capital Analysts Give CVS Health (CVS) a $73.00 Price Target” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2017/12/07/loop-capital-analysts-give-cvs-health-cvs-a-73-00-price-target.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
What are top analysts saying about CVS Health Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health Corp and related companies.